**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 79036

**Manuscript Type:** MINIREVIEWS

**Role of high dose vitamin C in management of hospitalised COVID-19 patients: A minireview**

Juneja D *et al*. High dose vitamin C in COVID-19

Deven Juneja, Anish Gupta, Sahil Kataria, Omender Singh

**Deven Juneja, Anish Gupta, Sahil Kataria, Omender Singh,** Institute of Critical Care Medicine, Max Super Speciality Hospital, Saket, New Delhi 110017, India

**Author contributions:** Juneja D, Gupta A, and Kataria S performed the majority of the writing, prepared the tables, and performed data accusation; Singh O provided the input in writing the paper and reviewed the manuscript.

**Corresponding author: Deven Juneja, DNB, FCCP, MBBS, Director,** Institute of Critical Care Medicine, Max Super Speciality Hospital, 1 Press Enclave Road, Saket, New Delhi 110017, India. devenjuneja@gmail.com

**Received:** July 29, 2022

**Revised:** August 22, 2022

**Accepted:** **September 1, 2022**

**Published online:**

**Abstract**

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has emerged as one of the most dreadful viruses the mankind has witnessed. It has caused world-wide havoc and wrecked human life. In our quest to find therapeutic options to counter this threat, several drugs have been tried, with varying success. Certain agents like corticosteroids, some anti-virals and immunosuppressive drugs have been found useful in improving clinical outcomes. Vitamin C, a water-soluble vitamin with good safety profile, has been tried to reduce progression and improve outcomes of patients with coronavirus disease 2019 (COVID-19). Because of its anti-oxidant and immunomodulatory properties, the role of vitamin C has expanded well beyond the management of scurvy and it is increasingly been employed in the treatment of critically ill patients with sepsis, septic shock, acute pancreatitis and even cancer. However, in spite of many case series, observational studies and even randomised control trials, the role of vitamin C remains ambiguous. In this review, we will be discussing the scientific rationale and the current clinical evidence for using high dose vitamin C in the management of COVID-19 patients.

**Key Words:** Ascorbic acid; COVID-19; SARS-CoV-2; Vitamin C

Juneja D, Gupta A, Kataria S, Singh O. Role of high dose vitamin C in management of hospitalised COVID-19 patients: A minireview. *World J Virol* 2022; In press

**Core Tip:** Vitamin C has several biochemical effects including anti-oxidant, anti-inflammatory, immuno-modulatory, and anti-viral properties which could make it a possible low-risk, add on to the current therapeutic options for managing coronavirus disease 2019 (COVID-19) patients. As it is a water-soluble vitamin, even high doses have been shown to be safe and only rarely, complications have been reported. In the last couple of years, many case series, observational studies and even randomised control trials have been conducted to evaluate the role of vitamin C in COVID-19, but have shown conflicting results. Hence, as per the current clinical evidence, the role of vitamin C remains ambiguous and it cannot be recommended as a part of routine therapeutic regimen for managing COVID-19 patients.

**INTRODUCTION**

Viruses have always been potential threats and posed challenges to human health. Historically, various respiratory viruses like severe acute respiratory virus (SARS-CoV) in 2002, H1N1 influenza virus in 2009 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 have created havoc and wrecked human life. In December 2019, in Wuhan, China, the first pneumonia outbreak secondary to COVID was reported. It was given an interim name of 2019-nCoV by the World Health Organisation and was later renamed SARS CoV-2 by the International Committee on Taxonomy of Viruses.

SARS CoV-2 is one of the most dreadful viruses faced by mankind which not only led to the COVID outbreak in China but also spread throughout the world infecting more than 528 million people with more than 6.3 million deaths worldwide[1]. This virus led to a disease with a varied clinical spectrum ranging from asymptomatic viral carriers to severe disease characterised by acute respiratory distress syndrome (ARDS)[2,3].The majority of affected individuals had mild symptoms especially in the initial stages of infection but many patients developed life threatening complications in the later stages with ARDS and consequent multiorgan failure leading to mortality of 7%-10%, especially in the elderly and those with pre-existing comorbidities[2-4].

The primary mechanism by which the virus caused severe disease was the initiation and propagation of a hyperimmune response, which increased pro-inflammatory cytokines and serum biomarkers[5]. The initial viral cytopathic effects were later complicated by a cytokine storm which led to ARDS and other systemic organ involvement[6].In lieu of this cytokine storm, various anti-inflammatory and immune-modulating medications like corticosteroids, interleukin-6 (IL-6) inhibitors, and Janus kinase (JAK) inhibitors have been tried to prevent, as well as treat this life threatening complication.

Vitamin C was one of the most commonly prescribed medications for all patients of COVID-19, irrespective of the severity of the disease. Vitamin C is an essential water-soluble vitamin which is required in humans for collagen synthesis, wound healing, bone development, various biochemical functions, redox reactions, synthesis of carnitine, adrenal steroids and catecholamines and metabolism of amino acids and cholesterol[7]. Over the years, its clinical role has expanded and is now commonly prescribed to treat myriad of severe diseases including sepsis, septic shock, acute pancreatitis and even cancer[8-10]. However, its role in these disease conditions remain controversial. Vitamin C has also been suggested as a potential therapeutic option in managing COVID-19 patients, with a few reports showing a beneficial role[11]. However, larger trials have reported variable outcomes, precluding definitive conclusions on vitamin C use in COVID-19 patients[12-14].

**RATIONALE**

The pathophysiology of COVID-19 remains incompletely understood. However, some pathophysiological changes, cytokine storm, micro thrombosis and immune-paralysis, have been described, which may lead to multi-organ dysfunction and death attributable to COVID-19. Another important phenomenon is release of oxygen free radicals (OFRs), causing oxidative damage and end-organ failure. These pathophysiological changes are similar to those seen with sepsis and septic shock, and hence, it was postulated that the use of vitamin C might be clinically beneficial in managing COVID-19.

***Vitamin C deficiency***

The normal plasma levels of vitamin C have been described above 50 μmol/L[15]. It is further suggested that although these levels may be sufficient to prevent scurvy, higher levels may be required to strengthen the immune system[16].However, these levels quickly fall in patients with acute illness, and vitamin C deficiency, defined as levels below 11 μmol/L, is commonly reported among hospitalized patients[17-19].

Studies in critically ill COVID-19 patients have also shown low mean vitamin C levels. In addition, levels were significantly lower among non-survivors as compared with survivors[20]. In a single center study of patients with COVID-19 associated ARDS, more than 90% had almost undetectable serum vitamin C levels[21]. It is postulated that the reason for vitamin C deficiency observed in acute illnesses like infections, trauma, and surgery is the increase in metabolic consumption[22].

***Anti-oxidant properties***

Vitamin C has well described anti-oxidant properties, which may help in scavenging OFRs by increasing nitric oxide levels. It also prevents production of nitrogen species, improving capillary blood flow[23].

***Anti-inflammatory properties***

Vitamin C has several anti-inflammatory effects, potentially having clinical benefits in managing COVID-19 induced cytokine storm. It inhibits tumor necrosis factor-α (TNF-α), suppresses activation of nuclear factor kappa-B (NF-kB), reduces pro-inflammatory cytokines and lowers histamine levels[24].

***Immune enhancing properties***

By affecting lipid synthesis and reinforcing the maintenance of the alveolar epithelial barrier, vitamin C helps in improving innate immunity. Vitamin C potentially helps in immunomodulation by increasing the immunoglobin and complement levels[25].It also exhibits immunomodulatory properties by promoting T-cell maturation and modulation, improving neutrophil chemotaxis and phagocytosis and by enhancing oxidative killing. In addition, it also promotes lymphocytic proliferation, interferon production and increases antibody production[23,24].

***Prevention of micro and macro vascular dysfunction***

Vitamin C acts as a co-factor for synthesis of catecholamines (epinephrine, norepinephrine), and vasopressin and increases the sensitivity of vascular musculature to these compounds. Vitamin C also causes inhibition of inducible nitric oxide synthase (iNOS) expression, thereby preventing vasoconstriction. These effects may be particularly helpful in patients with shock and may improve end-organ perfusion[23,24].

***Anti-viral properties***

Vitamin C has been shown to have direct and indirect effects on viral replication and can inactivate several viruses *in vitro*[26].High-dose vitamin C may cause viral inactivation by oxidation of viral nucleic acids and damage to viral capsids. Vitamin C can also have indirect effects by promoting interferon production, which may, in-turn affect viral replication by binding to the cell surface. Interferons may also aid in immune-stimulation leading to virus inactivation[27].Because of these anti-viral properties, vitamin C has been used clinically to manage viral illnesses ranging from common cold to viral ARDS secondary to wide range of viruses like enterovirus/rhinovirus, H1N1, and CHIKV[28-31].

***Other miscellaneous effects***

By reducing oxidation injury and apoptosis vitamin C plays a role in prevention of mitochondrial dysfunction. In addition, it also prevents septic cardiomyopathy by reducing oxidation injury and apoptosis and by increasing carnitine synthesis[23,24]. Hence, it may prove useful in managing viral myocarditis and improving cardiac dysfunction.

**CLINICAL EVIDENCE**

The first large randomized clinical trial (RCT) to evaluate the effect of vitamin C in COVID-19 patients was the COVID A to Z trial. It was a multicentre open label RCT which aimed to assess the effect of high dose zinc (50 mg), high dose ascorbic acid (8000 mg per day in 2-3 divided doses, orally) or a combination of both zinc and ascorbic acid on the duration of symptoms of SARS-COV 2. A total of 214 patients were enrolled in the study and randomised equally into 4 groups to receive a 10-d course of either zinc gluconate, ascorbic acid, both or only standard of care. The study’s primary end point was the number of days required for a reduction in symptoms (fever, cough, shortness of breath, and fatigue) by 50%. The results of the study did not show any significant decrease in the duration of symptoms as compared to standard of care. Additionally, there was no statistically significant difference in the need for hospitalisation and mortality[32].

Even though vitamin C is widely prescribed in the management of COVID-19 patients, the scientific evidence is primarily derived from case series and retrospective studies (Table 1)[11,14,33-42]. Only a few RCTs have been conducted to evaluate the role of high dose intravenous vitamin C (HDIVC) in hospitalised COVID-19 patients[12,13,43,44]. The largest RCT was a Pakistani study, which included 150 patients, 75 each in study and control groups. Patients in the study group were given 50 mg/kg/d of IV vitamin C and compared to those who received only the standard therapy. The authors reported that the patients who received IV vitamin C became symptom-free earlier and had reduced hospital length of stay (LOS)[13]. However, there was no significant difference in the need for invasive mechanical ventilation (IMV) and mortality. Other RCTs also failed to show any difference in the need for IMV or reduction in mortality rates (Table 1)[12,43,44].

A few studies showed a reduction in inflammatory markers[11,33,35,36,38] but these results were neither consistent nor translated in to improved clinical outcomes[33]. One small retrospective cohort study even reported increased mortality in COVID-19 patients treated with IV vitamin C 1.5 gm every 6th hourly for four days[37].

A few meta-analyses have also been published evaluating the role of vitamin C in COVID-19 (Table 2)[45-47]. Rawat *et al*[47] performed a meta-analysis on the impact of Vitamin C on major clinical outcomes such as mortality, intensive care unit (ICU) admission, duration of hospital stay and need for mechanical ventilation in patients diagnosed with COVID-19. They included 6 RCTs in their analysis encompassing 572 patients. Amongst the 6 studies, 2 were multicenter RCTs, and 4 were single centre studies. Two studies were conducted on non-severe patients, while 4 studies were conducted on severe cases of COVID-19. Both oral (2 studies) and intravenous vitamin C (4 studies) were used, and the dosage ranged from 50 mg/kg/d to 24 g per day of vitamin C. The meta-analysis did not show vitamin C to reduce any major outcomes in COVID-19 patients. Even in a subgroup analysis based on the dose, route of administration and severity of illness, no significant benefit was observed. However, this meta-analysis had multiple limitations including heterogeneity in the study population, variable doses of vitamin C and differences in route of administration. In defense, the subgroup analysis also revealed similar results. Moreover, some studies used combination of vitamin E and melatonin, which may have confounded the results. Also, the standard treatment used in the control groups differed and the data on the adverse effects of vitamin C was lacking[47].

A recently published meta-analysis analysed data from five trials in which only HDIVC, defined as IV vitamin C ≥ 2 gm/d, was prescribed to hospitalised COVID-19 patients. Among the included studies, three were RCTs, and two were retrospective studies, including 374 patients. The authors could not find any statistically significant difference in terms of hospital LOS, mortality or adverse effects when patients were treated with HDIVC[46].

Another larger meta-analysis, including seven trials and 807 patients analysing the role of HDIVC, also failed to show any beneficial results in terms of mortality, hospital or ICU LOS or need for IMV in COVID-19 patients. The authors further noted that all the included trials were of high quality but different dosing regimens were used ranging from 2-24 gm of IV vitamin C per day for 3-7 d[45].

Recognising the lack of clinical evidence, the current National Institutes of Health (NIH) guidelines also does not make any recommendation for or against the use of vitamin C in the management of out-patient or hospitalised COVID-19 patients[48].

**DOSING**

Both oral and intravenous formulations of vitamin C have shown similar clinical efficacy, but intravenous route is generally preferred in critically ill patients[49,50]. It is suggested that higher doses of vitamin C, 2-3 gm/day, may be required to maintain the normal serum concentrations in patients with acute viral infections[51].High doses of up to 100 g/d have been tried in the management of sepsis patients[52]. Although there is no consensus, any dose above 2 g/d is arbitrarily considered as high dose[46].

Even though several different dosing regimens have been tried in patients with COVID-19, data regarding dosing regimens are generally extrapolated from the trials on sepsis patients. Six hourly dosing have been shown to rapidly improve serum vitamin C levels, achieve a steady state and maintain therapeutic levels[53,54]. However, no consensus presently exists on the recommended daily dosage regimen for HDIVC.

**ADVERSE EFFECTS**

Even when used in high doses, vitamin C is considered harmless as it is a water-soluble vitamin. The major trials have mainly concentrated on the efficacy of vitamin C, and the data regarding adverse effects are primarily derived from case reports and series[55]. Most reported adverse effects are mild and reversible (Table 3)[55-57]. Rarely, patients may develop serious adverse effects, including haemolysis, disseminated intravascular coagulation and acute kidney injury (AKI). Adverse effects have been reported with both oral and intravenous preparations and the use of normal doses and high doses of vitamin C. Patients with underlying renal dysfunction and glucose-6-phosphate dehydrogenase (G6PD) deficiency are especially more prone to develop side effects like AKI and haemolysis[55].

**FUTURE DIRECTIONS**

Almost 50 trials are presently being conducted to evaluate the role of vitamin C in patients with COVID-19 disease. These trials are being conducted in patients with different severity of disease and are trying to assess different clinical outcomes ranging from the need for hospitalisation, resolution of symptoms, need for organ support, need for IMV and mortality. Role of vitamin C is also being explored in combination with other therapies like zinc, quercetin, and curcumin and comparison to other anti-oxidants like vitamin E, melatonin, pentoxifylline, and N-acetyl cysteine. These trials may help us better understand vitamin C’s clinical efficacy and safety profile and clarify its potential role in the management of COVID-19 patients. Also, these studies may shed light on the dosing of HDIVC, as most of the studies performed till now have used different dosing regimens, which might have affected their results.

**CONCLUSION**

Vitamin C is a relatively safe therapeutic option, and there may be scientific rationale which theoretically may help in the recovery of COVID-19 patients. Many observational studies and some RCTs have been conducted to evaluate its role in COVID-19. However, presently there is dearth of clinical evidence showing its utility in the management of COVID-19 patients; hence, it cannot be recommended for routine use in these patients. Further larger multi-center RCTs are warranted to prove its safety and potential role.

**REFERENCES**

1 **World health organization**. WHO Coronavirus (COVID-19) dashboard. [cited 27 July 2022]. Available from: https://covid19.who.int

2 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

3 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

4 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

5 **Liu F**, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol* 2020; **127**: 104370 [PMID: 32344321 DOI: 10.1016/j.jcv.2020.104370]

6 **Yang X**, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**: 475-481 [PMID: 32105632 DOI: 10.1016/S2213-2600(20)30079-5]

7 **Ströhle A**, Wolters M, Hahn A. Micronutrients at the interface between inflammation and infection--ascorbic acid and calciferol: part 1, general overview with a focus on ascorbic acid. *Inflamm Allergy Drug Targets* 2011; **10**: 54-63 [PMID: 21184650 DOI: 10.2174/187152811794352105]

8 **Marik PE**, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. *Chest* 2017; **151**: 1229-1238 [PMID: 27940189 DOI: 10.1016/j.chest.2016.11.036]

9 **Gao L**, Chong E, Pendharkar S, Phillips A, Ke L, Li W, Windsor JA. The Challenges and Effects of Ascorbic Acid Treatment of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies. *Front Nutr* 2021; **8**: 734558 [PMID: 34765629 DOI: 10.3389/fnut.2021.734558]

10 **Mussa A**, Mohd Idris RA, Ahmed N, Ahmad S, Murtadha AH, Tengku Din TADAA, Yean CY, Wan Abdul Rahman WF, Mat Lazim N, Uskoković V, Hajissa K, Mokhtar NF, Mohamud R, Hassan R. High-Dose Vitamin C for Cancer Therapy. *Pharmaceuticals (Basel)* 2022; **15** [PMID: 35745630 DOI: 10.3390/ph15060711]

11 **Hiedra R**, Lo KB, Elbashabsheh M, Gul F, Wright RM, Albano J, Azmaiparashvili Z, Patarroyo Aponte G. The use of IV vitamin C for patients with COVID-19: a case series. *Expert Rev Anti Infect Ther* 2020; **18**: 1259-1261 [PMID: 32662690 DOI: 10.1080/14787210.2020.1794819]

12 **Zhang J**, Rao X, Li Y, Zhu Y, Liu F, Guo G, Luo G, Meng Z, De Backer D, Xiang H, Peng Z. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. *Ann Intensive Care* 2021; **11**: 5 [PMID: 33420963 DOI: 10.1186/s13613-020-00792-3]

13 **Kumari P**, Dembra S, Dembra P, Bhawna F, Gul A, Ali B, Sohail H, Kumar B, Memon MK, Rizwan A. The Role of Vitamin C as Adjuvant Therapy in COVID-19. *Cureus* 2020; **12**: e11779 [PMID: 33409026 DOI: 10.7759/cureus.11779]

14 **Suna K**, Melahat UŞ, Murat Y, Figen ÖE, Ayperi Ö. Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia. *Med Clin (Barc)* 2022; **158**: 356-360 [PMID: 34103164 DOI: 10.1016/j.medcli.2021.04.010]

15 **European Food Safety Authority Panel on Dietetic Products**, Nutrition and Allergies. Scientific opinion on dietary reference values for vitamin C. *EFSA J* 2013; 11: 3418 [DOI: 10.2903/j.efsa.2013.3418]

16 **Berger MM**, Bischoff-Ferrari HA, Zimmermann M, Herter I, Spieldenner J, Eggersdorfer M. White Paper on Nutritional Status in Supporting a Well-Functioning Immune System for Optimal Health with a Recommendation for Switzerland; SGE: Bern, Switzerland, 2020. [cited 20 June 2022]. Available from: https://crnusa.org/sites/default/files/SSAC/2020.09.010%20SGE%20Nutritional%20status%20in%20supporting%20a%20well-functioning%20immune%20system%20for%20optimal%20health%20with%20a%20recommendation%20for%20Switzerland.pdf

17 **Evans-Olders R**, Eintracht S, Hoffer LJ. Metabolic origin of hypovitaminosis C in acutely hospitalized patients. *Nutrition* 2010; **26**: 1070-1074 [PMID: 20018480 DOI: 10.1016/j.nut.2009.08.015]

18 **Teixeira A**, Carrié AS, Généreau T, Herson S, Cherin P. Vitamin C deficiency in elderly hospitalized patients. *Am J Med* 2001; **111**: 502 [PMID: 11690581 DOI: 10.1016/s0002-9343(01)00893-2]

19 **Fain O**, Pariés J, Jacquart B, Le Moël G, Kettaneh A, Stirnemann J, Héron C, Sitbon M, Taleb C, Letellier E, Bétari B, Gattegno L, Thomas M. Hypovitaminosis C in hospitalized patients. *Eur J Intern Med* 2003; **14**: 419-425 [PMID: 14614974 DOI: 10.1016/j.ejim.2003.08.006]

20 **Arvinte C**, Singh M, Marik PE. Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study. *Med Drug Discov* 2020; **8**: 100064 [PMID: 32964205 DOI: 10.1016/j.medidd.2020.100064]

21 **Chiscano-Camón L**, Ruiz-Rodriguez JC, Ruiz-Sanmartin A, Roca O, Ferrer R. Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome. *Crit Care* 2020; **24**: 522 [PMID: 32847620 DOI: 10.1186/s13054-020-03249-y]

22 **Marik PE**, Hooper MH. Doctor-your septic patients have scurvy!. *Crit Care* 2018; **22**: 23 [PMID: 29378661 DOI: 10.1186/s13054-018-1950-z]

23 **Carr AC**, Shaw GM, Fowler AA, Natarajan R. Ascorbate-dependent vasopressor synthesis: a rationale for vitamin C administration in severe sepsis and septic shock? *Crit Care* 2015; **19**: 418 [PMID: 26612352 DOI: 10.1186/s13054-015-1131-2]

24 **Marik PE**. Vitamin C for the treatment of sepsis: The scientific rationale. *Pharmacol Ther* 2018; **189**: 63-70 [PMID: 29684467 DOI: 10.1016/j.pharmthera.2018.04.007]

25 **Prinz W**, Bortz R, Bregin B, Hersch M. The effect of ascorbic acid supplementation on some parameters of the human immunological defence system. *Int J Vitam Nutr Res* 1977; **47**: 248-257 [PMID: 914459]

26 **Jariwalla RJ**, Harakeh S. Antiviral and immunomodulatory activities of ascorbic acid. *Subcell Biochem* 1996; **25**: 213-231 [PMID: 8821976]

27 **Murata A**, Uike M. Mechanism of inactivation of bacteriophage MS2 containing single-stranded RNA by ascorbic acid. *J Nutr Sci Vitaminol (Tokyo)* 1976; **22**: 347-354 [PMID: 827603 DOI: 10.3177/jnsv.22.347]

28 **Anderson TW**, Reid DB, Beaton GH. Vitamin C and the common cold: a double-blind trial. *Can Med Assoc J* 1972; **107**: 503-508 [PMID: 5057006]

29 **Uchide N**, Toyoda H. Antioxidant therapy as a potential approach to severe influenza-associated complications. *Molecules* 2011; **16**: 2032-2052 [PMID: 21358592 DOI: 10.3390/molecules16032032]

30 **Gonzalez MJ**, Miranda-Massari JR, Berdiel MJ, Duconge J, Rodríguez-López JL, Hunninghake R, Cobas-Rosario VJ. High Dose Intraveneous Vitamin C and Chikungunya Fever: A Case Report. *J Orthomol Med* 2014; **29**: 154-156 [PMID: 25705076]

31 **Fowler Iii AA**, Kim C, Lepler L, Malhotra R, Debesa O, Natarajan R, Fisher BJ, Syed A, DeWilde C, Priday A, Kasirajan V. Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome. *World J Crit Care Med* 2017; **6**: 85-90 [PMID: 28224112 DOI: 10.5492/wjccm.v6.i1.85]

32 **Thomas S**, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, Il'Giovine ZJ, Mehra R, McWilliams C, Nissen SE, Desai MY. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**: e210369 [PMID: 33576820 DOI: 10.1001/jamanetworkopen.2021.0369]

33 **Hess AL**, Halalau A, Dokter JJ, Paydawy TS, Karabon P, Bastani A, Baker RE, Balla AK, Galens SA. High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID-19. *Intern Emerg Med* 2022 [PMID: 35349005 DOI: 10.1007/s11739-022-02954-6]

34 **Zheng S**, Chen Q, Jiang H, Guo C, Luo J, Li S, Wang H, Li H, Zheng X, Weng Z. No significant benefit of moderate-dose vitamin C on severe COVID-19 cases. *Open Med (Wars)* 2021; **16**: 1403-1414 [PMID: 34616916 DOI: 10.1515/med-2021-0361]

35 **Zhao B**, Ling Y, Li J, Peng Y, Huang J, Wang Y, Qu H, Gao Y, Li Y, Hu B, Lu S, Lu H, Zhang W, Mao E. Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study. *Ann Palliat Med* 2021; **10**: 1599-1609 [PMID: 33222462 DOI: 10.21037/apm-20-1387]

36 **Zhao B**, Liu M, Liu P, Peng Y, Huang J, Li M, Wang Y, Xu L, Sun S, Qi X, Ling Y, Li J, Zhang W, Mao E, Qu J. High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study. *Front Pharmacol* 2021; **12**: 638556 [PMID: 33967773 DOI: 10.3389/fphar.2021.638556]

37 **Li M**, Ching TH, Hipple C, Lopez R, Sahibzada A, Rahman H. Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection. *J Pharm Pract* 2021: 8971900211015052 [PMID: 34098784 DOI: 10.1177/08971900211015052]

38 **Xia G**, Fan D, He Y, Zhu Y, Zheng Q. High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019. *Nutrition* 2021; **91-92**: 111405 [PMID: 34388587 DOI: 10.1016/j.nut.2021.111405]

39 **Gao D**, Xu M, Wang G, Lv J, Ma X, Guo Y, Zhang D, Yang H, Jiang W, Deng F, Xia G, Lu Z, Lv L, Gong S. The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study. *Aging (Albany NY)* 2021; **13**: 7020-7034 [PMID: 33638944 DOI: 10.18632/aging.202557]

40 **Xia G**, Qin B, Ma C, Zhu Y, Zheng Q. High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study. *Aging (Albany NY)* 2021; **13**: 20906-20914 [PMID: 34499050 DOI: 10.18632/aging.203503]

41 **Burugu HR**, Kandi V, Kutikuppala LVS, Suvvari TK. Activities of Serum Ferritin and Treatment Outcomes Among COVID-19 Patients Treated With Vitamin C and Dexamethasone: An Uncontrolled Single-Center Observational Study. *Cureus* 2020; **12**: e11442 [PMID: 33324525 DOI: 10.7759/cureus.11442]

42 **Alamdari DH**, Moghaddam AB, Amini S, Keramati MR, Zarmehri AM, Alamdari AH, Damsaz M, Banpour H, Yarahmadi A, Koliakos G. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. *Eur J Pharmacol* 2020; **885**: 173494 [PMID: 32828741 DOI: 10.1016/j.ejphar.2020.173494]

43 **Darban M**, Malek F, Memarian M, Gohari A, Kiani A, Emadi A, et al Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial. *J Cell Mol Anesth* 2021; **6**:164-7 [DOI:10.22037/jcma.v6i2.32182]

44 **JamaliMoghadamSiahkali S**, Zarezade B, Koolaji S, SeyedAlinaghi S, Zendehdel A, Tabarestani M, Sekhavati Moghadam E, Abbasian L, Dehghan Manshadi SA, Salehi M, Hasannezhad M, Ghaderkhani S, Meidani M, Salahshour F, Jafari F, Manafi N, Ghiasvand F. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. *Eur J Med Res* 2021; **26**: 20 [PMID: 33573699 DOI: 10.1186/s40001-021-00490-1]

45 **Ao G**, Li J, Yuan Y, Wang Y, Nasr B, Bao M, Gao M, Qi X. Intravenous vitamin C use and risk of severity and mortality in COVID-19: A systematic review and meta-analysis. *Nutr Clin Pract* 2022; **37**: 274-281 [PMID: 35148440 DOI: 10.1002/ncp.10832]

46 **Kwak SG**, Choo YJ, Chang MC. The effectiveness of high-dose intravenous vitamin C for patients with coronavirus disease 2019: A systematic review and meta-analysis. *Complement Ther Med* 2022; **64**: 102797 [PMID: 34953366 DOI: 10.1016/j.ctim.2021.102797]

47 **Rawat D**, Roy A, Maitra S, Gulati A, Khanna P, Baidya DK. Vitamin C and COVID-19 treatment: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Metab Syndr* 2021; **15**: 102324 [PMID: 34739908 DOI: 10.1016/j.dsx.2021.102324]

48 **NIH**. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. [cited 25 July 2022]. Available from: https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section\_86.pdf

49 **Hemilä H**, Chalker E. Vitamin C Can Shorten the Length of Stay in the ICU: A Meta-Analysis. *Nutrients* 2019; **11** [PMID: 30934660 DOI: 10.3390/nu11040708]

50 **Hemilä H**, Chalker E. Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: a meta-regression analysis. *J Intensive Care* 2020; **8**: 15 [PMID: 32047636 DOI: 10.1186/s40560-020-0432-y]

51 **de Grooth HJ**, Manubulu-Choo WP, Zandvliet AS, Spoelstra-de Man AME, Girbes AR, Swart EL, Oudemans-van Straaten HM. Vitamin C Pharmacokinetics in Critically Ill Patients: A Randomized Trial of Four IV Regimens. *Chest* 2018; **153**: 1368-1377 [PMID: 29522710 DOI: 10.1016/j.chest.2018.02.025]

52 **Somagutta MKR**, Pormento MKL, Khan MA, Hamdan A, Hange N, Kc M, Pagad S, Jain MS, Lingarajah S, Sharma V, Kaur J, Emuze B, Batti E, Iloeje OJ. The Efficacy of vitamin C, thiamine, and corticosteroid therapy in adult sepsis patients: a systematic review and meta-analysis. *Acute Crit Care* 2021; **36**: 185-200 [PMID: 34185986 DOI: 10.4266/acc.2021.00108]

53 **Fowler AA 3rd**, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S; Medical Respiratory Intensive Care Unit Nursing, Fisher BJ, Natarajan R. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. *J Transl Med* 2014; **12**: 32 [PMID: 24484547 DOI: 10.1186/1479-5876-12-32]

54 **Hudson EP**, Collie JT, Fujii T, Luethi N, Udy AA, Doherty S, Eastwood G, Yanase F, Naorungroj T, Bitker L, Abdelhamid YA, Greaves RF, Deane AM, Bellomo R. Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock. *Crit Care Resusc* 2019; **21**: 236-242 [PMID: 31778629]

55 **Juneja D**, Jain R, Nasa P. Vitamin C-induced Hemolysis: Meta-summary and Review of Literature. *Indian J Crit Care Med* 2022; **26**: 224-227 [PMID: 35712748 DOI: 10.5005/jp-journals-10071-24111]

56 **Padayatty SJ**, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. *PLoS One* 2010; **5**: e11414 [PMID: 20628650 DOI: 10.1371/journal.pone.0011414]

57 **Yanase F**, Fujii T, Naorungroj T, Belletti A, Luethi N, Carr AC, Young PJ, Bellomo R. Harm of IV High-Dose Vitamin C Therapy in Adult Patients: A Scoping Review. *Crit Care Med* 2020; **48**: e620-e628 [PMID: 32404636 DOI: 10.1097/CCM.0000000000004396]

**Footnotes**

**Conflict-of-interest statement:** There are no conflicts of interest to report.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 29, 2022

**First decision:** August 22, 2022

**Article in press:**

**Specialty type:** Critical care medicine

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Barve P, United States; Carlan SJ, United States; Emran TB, Bangladesh; Mrzljak A, Croatia **S-Editor:** Chen YL **L-Editor:** A **P-Editor:** Chen YL

**Table 1 Different studies** **evaluating the role of high dose intravenous Vitamin C in COVID-19**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **S. No.** | **Title** | **Year of publication** | **Country of origin** | **Study design** | **Sample size in the control arm** | **Sample size in the intervention arm** | **Intervention summary** | **Results in brief** |
| 1 | Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia[14] | 2022 | Turkey | Retrospective study | 170 patients | 153 patients | 2 g/d IV | No difference in mortality |
| 2 | High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID-19[33] | 2022 | USA | Retrospective cohort study | 75 patients | 25 patients | 3 gm 6 hrly for 7 d IV | HDIVC group had a prolonged hospital stay, prolonged ICU stay, and prolonged time to deathCRP levels were lower in the HDIVC group while other inflammatory markers (d-dimer and ferritin) were similar in both groups.HDIVC patients had significantly lower rates of IMV and cardiac arrest |
| 3 | Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial[43] | 2021 | Iran | RCT | 11 | 10 | IV vitamin C (2 g, q6hr), oral; melatonin (6 mg, 6 hourly), and oral zinc sulfate (50 mg, 6 hourly) for 10 d | No differences in PaO2/FiO2, CRP, ESR or LDH levels and ICU LOS |
| 4 | Pilot trial of high-dose vitamin C in critically ill COVID-19 patients[12] | 2021 | China | Multi center RCT | 29 in control | 27 treatment group | 12 g of vitamin C/50 ml every 12 h for 7 d at a rate of 12 mL/h IV | No difference in IMV free days at D28; no difference in 28-d mortality. Steady rise in the PaO2/FiO2 in vitamin C group |
| 5 | No significant benefit of moderate-dose vitamin C on severe COVID-19 cases[34] | 2021 | China | Retrospective cohort study | 327 | 70 | 2-4 gm/d | No significant difference in clinical improvement or mortality rate |
| 6 | Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study[35] | 2021 | China | Retrospective case series |  | 12 patients | 71 to 350 mg/kg/d for 3 d IV | Reduction in CRPImproved PaO2/FiO2 and SOFA score |
| 7 | High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study[36] | 2021 | China | Retrospective before-after study | 55 patients | 55 patients | 100 mg/kg/d IV for 7 d | Significant reduction in progression to severe disease.Reduced levels of CRP, D-dimer and APTT |
| 8 | Safety and effectiveness of high-dose vitamin C in patients with COVID-19: A randomized open-label clinical trial[44] | 2021 | Iran | Randomised open-label study | 30 patients | 30 patients | 6 g/d IV | Reduced temperature and improved SaO2 in HDIVC group. No difference in ICU or hospital mortalityLonger hospital LOS in HDIVC group |
| 9 | Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection[37] | 2021 | USA | Retrospective cohort study | 24 patients | 8 patients | 1.5 grams IV vitamin C every 6 h for up to 4 d | HDIVC group had higher rates of hospital mortality and mean SOFA scores post-treatment. No difference in daily vasopressor requirement or ICU LOS |
| 10 | High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019[38] | 2021 | China | Retrospective cohort study | 151 | 85 | 100 mg/kg every 6 h for day 1 followed by 100 mg/kg evry 12 h for the next 5 d | Significantly reduced inflammatory markers (hs-CRP, IL-6, TNF-alpha) |
| 11 | The efficiency and safety of high-dose vitamin C in patients with COVID-19: A retrospective cohort study[39] | 2021 | China | Retrospective cohort study | 30 | 46 | 6 g twice a day on day 1 followed by 6 gm once a day for 4 d IV | Reduced 28 d mortality. No change in oxygen support |
| 12 | High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: A retrospective cohort study[40] | 2021 | China | Retrospective cohort study | 62 | 51 | 100 mg/kg every 6 h for day 1 followed by 100 mg/kg evry 12 h for the next 5 d | HDIVC can ameliorate cardiac injury through alleviating hyperinflammation |
| 13 | The Role of Vitamin C as Adjuvant Therapy in COVID-19[13] | 2020 | Pakistan | RCT | 75 patients | 75 patients | 50 mg/kg/day of intravenous (IV) | Earlier resolution of symptoms and reduced hospital LOS. No significant difference in the need for IMV and mortality |
| 14 | Activities of serum ferritin and treatment outcomes among COVID-19 patients treated with vitamin c and dexamethasone:An uncontrolled single-center observational study[41] | 2020 | India | Prospective, observational study |  | 50 patients | NA | Mortality 6% |
| 15 | The use of IV vitamin C for patients with COVID-19: A case series[11] | 2020 | USA | Case series |  | 17 patients | 1 g every 8 h for 3 d IV | Significant decrease in inflammatory markers. Mortality 12% |
| 16 | Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial[42] | 2020 | Iran | Phase I clinical trial | 25 ICU COVID-19 patients. 5 received MCN as last resort | 25 healthy individuals | Methylene blue (1 mg/kg) along with vitamin C (1500 mg/kg) and N-acetyl Cysteine (1500 mg/kg) orally or intravenously | Reduced methhemoglobin levels, survival of 4/5 patients |

IV: Intravenously; HDIVC: High dose intravenous vitamin C; ICU: Intensive care unit; CRP: C-reactive protein; RCT: Randomised control trial; ESR: Erythrocyte sedimentation rate; LDH: Lactate dehydrogenase; LOS: Length of stay; IMV: Invasive mechanical ventilation; SOFA: Sequential organ failure assessment; APTT: Activated prothrombin time; IL: Interleukin; TNF: Tumour necrosis factor; MCN: Methylene blue; USA: United states; COVID-19: Coronavirus disease 2019; RCT: Randomised control trial; NA: Not available.

**Table 2 Meta-analyses evaluating the role of Vitamin C in COVID-19**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **S. No.** | **Title** | **Year of publication** | **Country of origin** | **Included studies** | **Included sample size** | **Results in brief** |
| 1 | Intravenous vitamin C use and risk of severity and mortality in COVID-19: A systematic review and meta-analysis[45] | 2022 | China | 7 studies (3 RCTs, 4 observational studies) | 807 patients | IV vitamin C treatment did not affect disease severity or mortality |
| 2 | The effectiveness of high-dose intravenous vitamin C for patients withcoronavirus disease 2019: A systematic review and meta-analysis[46] | 2022 | Korea | 5 studies (3 RCTs, 2 retrospective trials) | 374 patients (186 HDIVC and 184 control group) | No difference in hospital LOS or mortality |
| 3 | Vitamin C and COVID-19 treatment: A systematic review and metaanalysis of randomized controlled trials[47] | 2021 | India | 6 RCTs | 572 patients | Vitamin C treatment didn’t reducemortality, ICU LOS, hospital LOS or need for invasive mechanical ventilation |

RCT: Randomised control trial; IV: Intravenously; HDIVC: High dose intravenous vitamin C; LOS: Length of stay; ICU: Intensive care unit.

**Table 3 Adverse effects reported with vitamin C**

|  |  |
| --- | --- |
| **Item** | **Description** |
| General | Interference with laboratory tests, phlebitis, nausea, vomiting |
| Neuro-muscular | Lethargy, fatigue, muscle cramps, headache, altered mental status |
| Metabolic | Hyperglycemia, hypernatremia |
| Haematological | Haemolysis, disseminated intravascular coagulation, methemoglobinemia |
| Renal | Oxalosis, renal stones, acute kidney injury |